Platelet Consumption in Thrombocythemia Complicated by Erythromelalgia: Reversal by Aspirin

Summary

The involvement of platelets in the pathogenesis of erythromelalgia, a frequent and characteristic microvascular thrombotic manifestation in patients with primary thrombocythemia and polycythemia rubra vera, was investigated by measuring the survival and turnover of ⁵¹Cr labeled autologous platelets in 10 patients with thrombocythemia complicated by erythromelalgia, in 10 asymptomatic thrombocythemia patients and in 6 subjects with reactive thrombocytosis. The mean platelet survival time of the erythromelalgia patients was 4.2 ± 0.2 days, which is significantly decreased as compared with asymptomatic thrombocythemia patients (6.6 ± 0.3 days, p <0.001) and patients with reactive thrombocytosis (8.0 ± 0.4 days, p <0.001). The mean platelet survival time of asymptomatic thrombocythemia patients was significantly decreased (p <0.01) as compared with reactive thrombocytosis patients. Treatment of erythromelalgia with aspirin increased the mean platelet survival time from 4.0 ± 0.3 days to 6.9 ± 0.4 days (p <0.001) and was associated with an elevation of the platelet count of 216 ± 30 × 10⁹ platelets per liter (p <0.001). Coumadin failed to improve platelet survival or symptoms caused by erythromelalgia. The increased platelet consumption in erythromelalgia is attributed to the formation of platelet thrombi in the arterial microvasculature. This conclusion is supported by the ability of aspirin to interrupt platelet consumption and clinical features of erythromelalgia.

• References

• 1 Michiels JJ, Abels J, Steketee J, van Vliet HH D M, Vuzevski VD. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 1985; 102: 466-471
• 2 Michiels JJ, van Joost Th. Erythromelalgia and thrombocythemia: a causal relation. J Am Acad Dermatol 1990; 22: 107-111
• 3 Michiels JJ, Ten Kate FW J. Erythromelalgia in thrombocythemia of various myeloproliferative disorders. Am J Hematol 1992; 39: 131-136
• 4 Michiels JJ, Ten Kate FW J, Vuzevski VD. Histopathology of erythromelalgia in thrombocythaemia. Histopathology 1984; 8: 669-678
• 5 Vreeken J, van Aken WS. Spontaneous aggregation of blood platelets as a cause of idiopathic and recurrent painful toes and fingers. Lancet 1971; 2: 1394-1397
• 6 Mason JE, De Vita VT, Canellos GP. Thrombocytosis in chronic granulocytic leukemia: incidence and clinical significance. Blood 1974; 44: 483-487
• 7 Brodsky I, Hahn SB, Ross EM, Petkov G. Platelet and fibrinogen kinetics in the chronic myeloproliferative disorders. Cancer 1972; 30: 1444-1450
• 8 Wasserman LR. The treatment of polycythemia vera. Sem Hematol 1976; 14: 13-57
• 9 Murphy S, Iland H, Rosenthal D, Laszlo J. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Sem Hematol 1988; 23: 177-182
• 10 International Committee for Standardization in Hematology. Recommended methods for radioisotope platelet survival studies. Blood 1977; 50: 1137-1144
• 11 International Committee for Standardization in Hematology. Recommended method for Indium-111 platelet survival studies. J Nucl Med 1988; 29: 564-566
• 12 Schmidt KG, Rasmussen JP, Rasmussen AD, Arendrup H. Comparative studies of the in vivo kinetics of simultaneous injected ¹¹¹In- and ^5lCr- labeled human platelets. Scand J Haematol 1983; 30: 465-478
• 13 Dewanjee MK, Wahner HW, Dunn WL, Robertson JS, Offord KP, Fuster VD, Chesebro JH. Comparison of three platelet markers for measurement of platelet survival time in healthy volunteers. Mayo Clin Proc 1986; 61: 327-336
• 14 Wadenvik H, Kutti J. The in vivo kinetics of ¹¹¹In- and ^5lCr-labeled platelets: a comparative study using both stored and fresh platelets. Br J Haematol 1991; 78: 523-528
• 15 Murphy EA, Francis ME. The estimation of blood platelet survival I. General principles of the study of cell survival Thromb Diath Haemorrh 1969; 22: 281-295
• 16 Murphy EA, Francis ME. The estimation of blood platelet survival II. The multiple hit model Thromb Diath Haemorrh 1971; 25: 53-80
• 17 Harker LA. The kinetics of platelet production and destruction in man. Clin Haematol 1977; 6: 671-721
• 18 Harker LA, Finch C. Thrombokinetics in man. J Clin Invest 1969; 48: 963-974
• 19 Weinfeld A, Branehog I, Kutti J. Platelets in the myeloproliferative syndrome. Clin Haematol 1975; 4: 373-392
• 20 Bautista AP, Buckler PW, Towler HM A, Dawson AA, Bennett B. Measurement of platelet life-span in normal subjects and in patients with myeloproliferative disease with indium oxide labeled platelets. Br J Haematol 1984; 58: 679-687
• 21 Jabaily J, Iland HJ, Laszlo J, Massey EW, Faquet GB, Briere J, Landaw SA, Piscotta AV. Neurologic manifestations of essential thrombocythemia. Ann Int Med 1983; 99: 513-518
• 22 Michiels JJ, Koudstaal PJ, Mulder AH, van Vliet HH D M. Transient neurological and ocular manifestations in primary thrombocythemia. Neurology 1993; 43: 1107-1110
• 23 Scheffer MG, Michiels JJ, Simoons ML, Roelandt JR T C. Thrombocythemia and coronary heart disease. Am Heart J 1989; 22: 573-576